| Date | Title | Description |
| 27.08.2026 | Neurophet Supplies 'Neurophet AQUA' and 'Neurophet AQUA AD Plus' to Elevate Clinic in the U.S., Expanding Its Presence in the U.S. Brain Disorders Market | Provides solutions for analyzing brain atrophy and white matter hyperintensities, as well as monitoring side effects associated with Alzheimer's disease treatments
Secures a key reference site at a U.S. medical institution specializing in n... |
| 02.07.2026 | Neurophet Supplies 'Neurophet AQUA' to Raffles Medical in Singapore | Providing Neurophet AQUA capable of analyzing brain atrophy and white matter degeneration… Securing meaningful clinical reference
SEOUL, South Korea, July 2, 2026 /PRNewswire/ -- Neurophet (Co-CEOs Jake Junkil Been and Donghyeon Kim), an ar... |
| 16.06.2026 | Neurophet Showcases 'Brain Imaging AI Solutions' at BIO USA, Accelerates Global Business Development Collaborations | Introduces key products including an integrated brain imaging analysis solution for Alzheimer's disease treatment decision-making
Expands partnering efforts with global pharmaceutical and biotech companies as well as potential customers, wh... |
| 26.05.2026 | Neurophet Launches Joint Study with VHIR on 'Neurophet AQUA MS', Accelerating AI Algorithm Validation | Collaborative research on AI-based diagnosis of multiple sclerosis, Building a clinical trial dataset
Leveraging large-scale, multi-center brain MRI datasets to detect key lesion biomarkers
SEOUL, South Korea, May 26, 2026 /PRNewswire/ -- N... |
| 21.05.2026 | Neurophet Appoints Globally Renowned Imaging AI Expert Dr. Lawrence N. Tanenbaum as Scientific Advisor | Former Vice President and Chief Technology Officer of RadNet, one of the largest outpatient imaging providers in the United States
Appointment expected to strengthen clinical validation, global expansion, and competitiveness in neuroimaging... |
| 26.03.2026 | Neurophet Signs MOU with ALZ-NET to Facilitate Imaging Monitoring Infrastructure for Alzheimer's Disease Therapies | Aims to improve quality of care for patients with Alzheimer's disease… Exploring adoption of Neurophet's key solutions
Collaboration expected to leverage Neurophet AQUA, Neurophet SCALE PET and Neurophet AQUA AD Plus
SEOUL, South Korea, Mar... |
| 06.02.2026 | Neurophet Secures FDA 510(k) Clearance for "Neurophet AQUA AD Plus," Marking Its Third U.S. Regulatory Milestone | Following AQUA and SCALE PET, the latest FDA clearance reinforces Neurophet's leadership in AI-based Alzheimer's disease imaging analysis
Advanced analysis of neuroimaging features associated with cerebral microbleeds and edema supports ima... |
| 09.12.2025 | Neurophet Introduced Use Cases of Its AI-based Brain Imaging Analysis Solutions at the SEACURE Symposium Hosted by Nanyang Technological University in Singapore | Introduced brain-imaging analysis products, including Neurophet AQUA AD, which enables monitoring of adverse effects related to Alzheimer's disease treatments
Highlighted clinical value of Neurophet AQUA AD…To accelerate efforts across heal... |
| 30.09.2025 | Neurophet Publishes Clinical Validation Results of 'Neurophet AQUA' in Annals Academy of Medicine Singapore | - Clinical study conducted at the Dementia Research Centre, Nanyang Technological University, Singapore, involving Southeast Asian participants
- Expert level accuracy, while significantly reducing analysis time for white matter hyperintens... |
| 02.09.2025 | Neurophet Signs MoU with InRAD to Establish Global Standards for Alzheimer's disease and Dementia Data | Neurophet's AI-based brain imaging analysis solutions to support global standardization of Alzheimer's and other dementia-related data
Enhancing dementia research by integrating AI imaging solutions with real-world data platforms
SEOUL, Sou... |
| 31.07.2025 | Neurophet Showcases Full-Cycle Brain Imaging Analysis Solutions for Alzheimer's disease Including 'Neurophet AQUA AD' at AAIC 2025 | Showcased brain imaging analysis products such as Neurophet AQUA AD, capable of monitoring side effects of Alzheimer's disease treatments
Engaged in partnering with global big pharma and neurology KOLs, seeking global development collaborat... |
| 13.06.2025 | Neurophet Participates in BIO USA 2025: To showcase Brain Imaging Analysis Solutions Including 'Neurophet AQUA AD' | Highlight brain imaging analysis solutions, including 'Neurophet AQUA AD', which monitors side effects from Alzheimer's disease treatments
To accelerate partnering efforts with global pharmaceutical companies and potential clients, while ex... |
| 21.05.2025 | Neurophet Participates ASNR 2025: Showcasing Clinical Utility of 'Neurophet AQUA AD' | Co-CEO Jake Junkil Been joins Industry Collaboration Session to present Neurophet's brain imaging analysis technologies, including Neurophet AQUA AD
Company accelerates partnerships with global pharmaceutical companies and neurology KOLs to... |
| 26.02.2025 | Neurophet Presented Three Research Abstracts on Personalized tDCS at International Brain Stimulation Conference | - Showcased core technology and products for personalized tDCS at the conference in Kobe, Japan
- Presented clinical outcomes in disorders of consciousness, upper extremity function in patients with sub-acute and chronic stroke, and post-st... |
| 05.12.2024 | Neurophet to Participate in RSNA 2024: Unveiling Multiple Sclerosis Analysis Technology with Neurophet AQUA | Demonstrates MS Analysis Technology, Recently Secured FDA 510(k) Clearance
Introduces 'Neurophet AQUA AD,' a Total Solution for Alzheimer's Disease Treatment Prescription, at the AI Theater
SEOUL, South Korea, Dec. 5, 2024 /PRNewswire/ -- N... |
| 25.11.2024 | Neurophet Secures FDA 510(k) Clearance for Multiple Sclerosis Analysis with 'Neurophet AQUA' | New features include advanced analysis of multiple sclerosis (MS) and white matter hyperintensities alongside brain atrophy analysis
Accelerating global expansion with cutting-edge technology targeting MS, a prevalent condition in North Ame... |
| 15.11.2024 | Neurophet Appoints CTO Donghyeon Kim as Co-CEO, Joining Jake Junkil Been in Dual Leadership to Drive Global Growth | - Donghyeon Kim, Co-Founder and CTO of Neurophet, to Take On Dual Role as CEO, Heading Technology and Company Leadership
- Aims to Strategically Expand Business and Management Functions for Establishing a Strong Presence in Global Markets
S... |
| 31.10.2024 | Neurophet and Siemens Healthineers: A New Era in Medical Innovation in China | The landscape of medical technology is shifting. Two companies, Neurophet and Siemens Healthineers, are leading the charge in China. Their recent partnerships signal a new era of innovation, collaboration, and market expansion. Both compani... |
| 30.10.2024 | Neurophet partners with Beijing LADO Technology… Intends to establish Joint Venture in China | Neurophet enters into a strategic agreement with LADO to distribute Neurophet SCALE PET
Improves the efficiency of market entry with expertise of medical device go-to-market process in China through the establishment of joint venture
SEOUL,... |
| 19.10.2024 | Revolutionizing Alzheimer's Diagnosis: The Neurophet and AriBio Collaboration | In the realm of Alzheimer's disease, innovation is the lifeblood of hope. Neurophet, a South Korean AI company, is at the forefront of this revolution. Their recent partnership with AriBio, a biopharmaceutical firm, aims to reshape how we d... |
| 18.10.2024 | Neurophet to host Symposium featuring renowned expert in Alzheimer's disease treatment from the U.S. | - Invited Neurophet's scientific advisor Stephen Salloway, professor of Neurology at Brown Medical School as guest speaker
- Shared latest insights on brain image analysis used for prescription of Alzheimer's disease treatments such as 'Leq... |
| 15.10.2024 | Neurophet-AriBio to develop 'Next-Gen Platform for Alzheimer's diagnosis' | - Neurophet's brain MRI analysis technology incorporates fluid biomarker data from AriBio's global Phase 3 clinical trial for Alzheimer's disease
- Collaborates leveraging Neurophet's medical image analysis technology and AriBio's clinical ... |
| 04.10.2024 | Indian mental health app Lissun takes on AI with $3M and more briefs | Photo: Pixabay/Pexels
Mental health app Lissun bags $3M for AI integration
Mental health platform Lissun in India has scored $2.5 million in a pre-Series A funding round led by RPSG Capital Ventures.
With its fresh funds, the startup plans ... |
| 09.09.2024 | Neurophet-NTU Singapore, recognized for outstanding joint research | - Neurophet accelerates global expansion for research and partnership in AI-driven brain image analysis
SEOUL, South Korea, Sept. 9, 2024 /PRNewswire/ -- Neurophet, an artificial intelligence (AI) solution company for brain disease, announc... |
| 27.07.2024 | The Future of Brain Health: Innovations and Leadership in Alzheimer's and Multiple Sclerosis Treatments | In the ever-evolving landscape of biotechnology, two companies are making waves in the treatment of chronic neurological diseases: Immunic, Inc. and Neurophet. Both are leveraging advanced technologies and seasoned leadership to tackle the ... |
| 25.07.2024 | Neurophet to launch total solution for AD treatments 'Neurophet AQUA AD' at AAIC 2024 | - Demonstrates Neurophet AQUA AD for AD treatments such as Leqembi and Kisunla
- Introduces updated version of Neurophet SCALE PET with centiloid scale feature
SEOUL, South Korea, July 25, 2024 /PRNewswire/ -- Neurophet, an artificial intel... |
| 25.07.2024 | Neurophet to launch total solution for AD treatments 'Neurophet AQUA AD' at AAIC 2024 | - Demonstrates Neurophet AQUA AD for AD treatments such as Leqembi and Kisunla
- Introduces updated version of Neurophet SCALE PET with centiloid scale feature
SEOUL, South Korea, July 25, 2024 /PRNewswire/ -- Neurophet, an artificial intel... |
| 26.06.2024 | Neurophet to present brain stimulation simulation study at OHBM 2024 | - Presents a poster identifying tDCS effects for patients with AD and cognitively normal people
- Showcases brain imaging treatment planning software for electric brain stimulation Neurophet tESplan Plus
SEOUL, South Korea, June 26, 2024 /P... |
| 31.05.2024 | Neurophet to participate BIO USA… exploring global partnership and business | Neurophet's AI brain image analysis technology improves time and cost efficiency for drug development
Aims to create business opportunities with global pharmaceutical companies
SEOUL, South Korea, May 31, 2024 /PRNewswire/ -- Neurophet, an ... |
| 17.11.2023 | Neurophet gears for 2024 IPO after $15M Series C raise and more digital health fundings | Photo courtesy of Neurophet |
| - | NEUROPHET | “Neurophet” |
